ABH hydrochloride
Based on 1 publication(s) in Google Scholar
ABH (hydrochloride) is an orally active arginase inhibitor (Ki = 8.5 nM). ABH hydrochloride promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH hydrochloride improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.90%
- CAS. Nr.: 194656-75-2
- Formel: C6H15BClNO4
- Molecular Weight:211.45
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Covalent Screening Library
HY-L036
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Chemokine Compound Library
HY-L132
-
Metabolic Enzyme Compound Library
HY-L146
-
Boronic Acid Compound Library
HY-L167
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) ABH hydrochloride
More
Biologische Aktivität
ABH (100 μM; pretreatment for 1 h, hypoxia for 12-24 h) hydrochloride partially prevents the hypoxia-induced reduction in in-vitro tube-like structure formation in bovine aortic endothelial cells and increased vascular endothelial growth factor (VEGF) expression[2].
ABH (0-10 μM; 3 h) hydrochloride effectively inhibits arginase from multiple Bacillus anthracis spore strains[3].
ABH (0.01-1 mM; pretreatment for 1 h) hydrochloride significantly reduces arginase activity in mouse dermal fibroblasts, with 0.1 mM ABH reducing arginase activity by 35% and 1 mM ABH reducing arginase activity by 54%[5].
ABH (100 μM; pretreatment for 1 h) hydrochloride can inhibit the increase in arginase 1 (A1) expression and activity in mouse aortic endothelial cells induced by high glucose/palmitic acid, maintain NO production, reduce the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1), and inhibit monocyte adhesion[7].
ABH (100 µM; 2 h) hydrochloride inhibits Ang II-induced proliferation of rat aortic smooth muscle cells, ODC activity and expression, and the increase in type I collagen and hydroxyproline levels[10].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
ABH (0.1 mM, 0.1 mL; topical application; once every 8 hours; 14 days) hydrochloride can significantly promote wound healing in mice[5].
ABH (5 mg/kg; s.c.; once 1 hour before surgery; single administration) hydrochloride can increase plasma nitrite levels in rats with pneumoperitoneum, maintain nitric oxide synthase (NOS) activity, reduce oxidative stress and inflammatory response, and reduce the severity of lung injury[6].
ABH (10 mg/kg; p.o., drinking water; once daily) hydrochloride can inhibit the increase of arginase activity and A1 expression in vascular endothelial cells of obese mice induced by a high-fat and high-sugar diet, reduce inflammation and pathological remodeling of visceral adipose tissue (VAT), including reducing inflammatory monocyte infiltration, macrophage polarization to M1 type, improving adipocyte size, fibrosis and capillary density[7].
ABH (100 mg; i.p.; once at 24, 48, 60, 70 h after infection or continuously administered until day 3 after infection) hydrochloride can increase NO production in the lungs of mice infected with Pseudomonas aeruginosa, improve L-arginine availability, reduce L-ornithine concentration, and do not increase the levels of lung inflammatory markers[8].
ABH (400 µg/kg/day; subcutaneous osmotic pump injection; once/day; 21 days) hydrochloride can reduce the mean arterial blood pressure and improve the vascular reactivity of the carotid and femoral arteries in a rat model of hypertension induced by chronic intermittent hypoxia (CIH)[9].
ABH (10 mg/kg/day; drinking water administration; continuous administration; 6 months) hydrochloride can improve endothelial function, reduce aortic stiffness and fibrosis, and reduce plasma and aortic arginase activities in a mouse model of obesity-related type 2 diabetes induced by a high-fat and high-sugar diet[10].
ABH (400 µg/day; subcutaneous osmotic pump administration; continuous administration) hydrochloride can preserve the total volume of the fetal lung, prevent excessive proliferation of pulmonary vascular smooth muscle cells, and improve the number of pulmonary vessels and lung morphology in a rat model of congenital diaphragmatic hernia (CDH) induced by Nitrofen (HY-B1877)[11].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:9-11 weeks old, male C57BL/6 mice, full-thickness dorsal excisional wound model[5]
-
Dosage:0.1 mM in saline
-
Administration:Topical application, every 8 hours for 14 days
-
Result:Accelerated wound closure 7-14 days post-surgery.
Increased wound granulation tissue and decreased connective tissue on postoperative day 3.
Enhanced re-epithelialization and changed the localization of myofibroblasts on postoperative day 7. Increased NOx levels in the wound on day 3.
Chemical Information
-
CAS. Nr. 194656-75-2
-
Appearance Solid
-
Molecular Weight 211.45
-
Formel C6H15BClNO4
-
Color White to off-white
-
SMILES
O=C([C@H](CCCCB(O)O)N)O.[H]Cl
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Time-Controlled Refrigerated Stem Cell Therapy Mitigates Scleroderma Fibrosis via Modulation of Mitochondrial Autophagy and Gut Metabolism. [Abstract]2026 Mar 31:e15505. PMID: 41915839
Lösungsmittel & Löslichkeit
H2O : 100 mg/mL (472.93 mM; Need ultrasonic)
DMSO : 100 mg/mL (472.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (11.82 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (11.82 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[2]. Wang L, et al. Arginase inhibition enhances angiogenesis in endothelial cells exposed to hypoxia. Microvasc Res. 2015 Mar;98:1-8. [Content Brief]
[3]. Tsai P, et al. Effect of the mammalian arginase inhibitor 2(S)-amino-6-boronohexanoic acid on Bacillus anthracis arginase. Curr Microbiol. 2012 Apr;64(4):379-84. [Content Brief]
[4]. Segal R, et al. Chronic oral administration of the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) improves erectile function in aged rats. J Androl. 2012 Nov-Dec;33(6):1169-75. [Content Brief]
[5]. Kavalukas SL, et al. Arginase inhibition promotes wound healing in mice. Surgery. 2012 Feb;151(2):287-95. [Content Brief]
[6]. Cho JS, et al. The effects of arginase inhibitor on lung oxidative stress and inflammation caused by pneumoperitoneum in rats. BMC Anesthesiol. 2015 Sep 28;15:129. [Content Brief]
[7]. Yao L, et al. Obesity-induced vascular inflammation involves elevated arginase activity. Am J Physiol Regul Integr Comp Physiol. 2017 Nov 1;313(5):R560-R571. [Content Brief]
[8]. Mehl A, et al. Effect of arginase inhibition on pulmonary L-arginine metabolism in murine Pseudomonas pneumonia. PLoS One. 2014 Mar 3;9(3):e90232. [Content Brief]
[9]. Krause BJ, et al. Chronic Intermittent Hypoxia-Induced Vascular Dysfunction in Rats is Reverted by N-Acetylcysteine Supplementation and Arginase Inhibition. Front Physiol. 2018 Jul 24;9:901. [Content Brief]
[11]. Toso A, et al. Congenital diaphragmatic hernia: phosphodiesterase-5 and Arginase inhibitors prevent pulmonary vascular hypoplasia in rat lungs. Pediatr Res. 2024 Mar;95(4):941-948. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.7293 mL | 23.6463 mL | 47.2925 mL | 118.2313 mL |
| 5 mM | 0.9459 mL | 4.7293 mL | 9.4585 mL | 23.6463 mL | |
| 10 mM | 0.4729 mL | 2.3646 mL | 4.7293 mL | 11.8231 mL | |
| 15 mM | 0.3153 mL | 1.5764 mL | 3.1528 mL | 7.8821 mL | |
| 20 mM | 0.2365 mL | 1.1823 mL | 2.3646 mL | 5.9116 mL | |
| 25 mM | 0.1892 mL | 0.9459 mL | 1.8917 mL | 4.7293 mL | |
| 30 mM | 0.1576 mL | 0.7882 mL | 1.5764 mL | 3.9410 mL | |
| 40 mM | 0.1182 mL | 0.5912 mL | 1.1823 mL | 2.9558 mL | |
| 50 mM | 0.0946 mL | 0.4729 mL | 0.9459 mL | 2.3646 mL | |
| 60 mM | 0.0788 mL | 0.3941 mL | 0.7882 mL | 1.9705 mL | |
| 80 mM | 0.0591 mL | 0.2956 mL | 0.5912 mL | 1.4779 mL | |
| 100 mM | 0.0473 mL | 0.2365 mL | 0.4729 mL | 1.1823 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
ABH hydrochloride Related Classifications
HY-112868B Related Classifications
Powered by Bioz